While several rodent models of NASH have demonstrated anti-steatosis and anti-inflammatory activity for FXR and PPAR agonists15,19,26–28, fibrosis-reversing effects are a rare feature of experimental anti-NASH agents. Here, NR1H4 is linked to metabolic dysfunction-associated steatohepatitis.